Equities Analysts Offer Predictions for WVE FY2026 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – B. Riley decreased their FY2026 EPS estimates for shares of Wave Life Sciences in a research note issued to investors on Thursday, April 10th. B. Riley analyst M. El-Saadi now forecasts that the company will earn ($1.15) per share for the year, down from their previous estimate of ($0.96). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.84 EPS.

A number of other brokerages have also recently issued reports on WVE. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. Wedbush started coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They set an “outperform” rating and a $18.00 price target for the company. Jefferies Financial Group started coverage on Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, March 26th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.18.

Wave Life Sciences Stock Up 4.7 %

WVE stock opened at $6.28 on Monday. The firm has a 50 day moving average of $9.21 and a two-hundred day moving average of $11.63. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The company has a market capitalization of $963.89 million, a price-to-earnings ratio of -5.66 and a beta of -0.93.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Institutional Investors Weigh In On Wave Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Wave Life Sciences during the 4th quarter valued at about $40,000. Quarry LP acquired a new stake in Wave Life Sciences during the fourth quarter valued at approximately $62,000. KBC Group NV bought a new stake in shares of Wave Life Sciences in the 4th quarter valued at approximately $67,000. Summit Investment Advisors Inc. raised its holdings in shares of Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after buying an additional 2,308 shares in the last quarter. Finally, Westwood Wealth Management acquired a new position in shares of Wave Life Sciences in the 4th quarter worth approximately $124,000. Institutional investors own 89.73% of the company’s stock.

Insider Activity at Wave Life Sciences

In other news, CEO Paul Bolno sold 169,025 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares of the company’s stock, valued at $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.